secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001193805-22-001504
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Q3 net loss $35.3M; CSL partnership $200M upfront, up to $4.3B milestones
--------------------------------------------------------------------------------

- Revenue $13.4M (Q3 2022) vs $2.4M YoY; net loss $35.3M ($1.33 per share).
- Cash $237.7M at Sep 30, 2022, down from $370.5M at Dec 31, 2021.
- CSL Seqirus collaboration: $200M upfront, up to $4.3B milestones, 40% profit share on COVID vaccines.
- BARDA award of up to $63.2M for self-amplifying mRNA pandemic influenza vaccine development.
- ARCT-810 OTC deficiency Phase 2 dosing starts Q4 2022; ARCT-032 CTA filing expected by year end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522001504/0001193805-22-001504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522001504/e618005_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-22-001504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer